Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
GO:00305958 | Endometrium | AEH | leukocyte chemotaxis | 41/2100 | 230/18723 | 1.81e-03 | 1.44e-02 | 41 |
GO:00447726 | Endometrium | AEH | mitotic cell cycle phase transition | 67/2100 | 424/18723 | 2.37e-03 | 1.78e-02 | 67 |
GO:00975299 | Endometrium | AEH | myeloid leukocyte migration | 39/2100 | 220/18723 | 2.55e-03 | 1.88e-02 | 39 |
GO:004340910 | Endometrium | AEH | negative regulation of MAPK cascade | 33/2100 | 180/18723 | 3.04e-03 | 2.15e-02 | 33 |
GO:000931410 | Endometrium | AEH | response to radiation | 70/2100 | 456/18723 | 3.99e-03 | 2.68e-02 | 70 |
GO:00515927 | Endometrium | AEH | response to calcium ion | 28/2100 | 149/18723 | 4.22e-03 | 2.79e-02 | 28 |
GO:00026889 | Endometrium | AEH | regulation of leukocyte chemotaxis | 24/2100 | 122/18723 | 4.25e-03 | 2.81e-02 | 24 |
GO:004668314 | Endometrium | AEH | response to organophosphorus | 25/2100 | 131/18723 | 5.39e-03 | 3.36e-02 | 25 |
GO:00071627 | Endometrium | AEH | negative regulation of cell adhesion | 49/2100 | 303/18723 | 5.43e-03 | 3.37e-02 | 49 |
GO:003367310 | Endometrium | AEH | negative regulation of kinase activity | 40/2100 | 237/18723 | 5.47e-03 | 3.38e-02 | 40 |
GO:001407414 | Endometrium | AEH | response to purine-containing compound | 27/2100 | 148/18723 | 7.34e-03 | 4.18e-02 | 27 |
GO:000646915 | Endometrium | AEH | negative regulation of protein kinase activity | 36/2100 | 212/18723 | 7.35e-03 | 4.18e-02 | 36 |
GO:00716756 | Endometrium | AEH | regulation of mononuclear cell migration | 22/2100 | 115/18723 | 8.42e-03 | 4.60e-02 | 22 |
GO:000697917 | Endometrium | EEC | response to oxidative stress | 99/2168 | 446/18723 | 9.02e-11 | 1.13e-08 | 99 |
GO:004854517 | Endometrium | EEC | response to steroid hormone | 77/2168 | 339/18723 | 3.80e-09 | 2.71e-07 | 77 |
GO:000030217 | Endometrium | EEC | response to reactive oxygen species | 57/2168 | 222/18723 | 4.04e-09 | 2.82e-07 | 57 |
GO:004254216 | Endometrium | EEC | response to hydrogen peroxide | 41/2168 | 146/18723 | 4.12e-08 | 2.29e-06 | 41 |
GO:003806612 | Endometrium | EEC | p38MAPK cascade | 21/2168 | 55/18723 | 3.30e-07 | 1.33e-05 | 21 |
GO:005140314 | Endometrium | EEC | stress-activated MAPK cascade | 55/2168 | 239/18723 | 3.98e-07 | 1.56e-05 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP1 | SNV | Missense_Mutation | | c.1516N>A | p.Cys506Ser | p.C506S | O94782 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
USP1 | SNV | Missense_Mutation | | c.1058N>T | p.Ser353Phe | p.S353F | O94782 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
USP1 | SNV | Missense_Mutation | novel | c.127C>G | p.Gln43Glu | p.Q43E | O94782 | protein_coding | tolerated(0.18) | benign(0.104) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | rs772351967 | c.962N>G | p.Tyr321Cys | p.Y321C | O94782 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.670N>G | p.Lys224Glu | p.K224E | O94782 | protein_coding | tolerated(0.82) | benign(0.033) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.1881N>T | p.Leu627Phe | p.L627F | O94782 | protein_coding | deleterious(0.04) | benign(0.376) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
USP1 | SNV | Missense_Mutation | novel | c.219G>C | p.Lys73Asn | p.K73N | O94782 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USP1 | insertion | In_Frame_Ins | novel | c.395_396insCGTTACTTCCAA | p.Asp131_Lys132insAsnValThrSer | p.D131_K132insNVTS | O94782 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
USP1 | insertion | Frame_Shift_Ins | novel | c.2072_2073insCTGCAGGTGCCCACCACCACGCCCGGCTAATTTTTTGTATTTT | p.Ser692CysfsTer15 | p.S692Cfs*15 | O94782 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
USP1 | SNV | Missense_Mutation | novel | c.748G>A | p.Glu250Lys | p.E250K | O94782 | protein_coding | tolerated(0.21) | benign(0.341) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-5510 | CHEMBL578741 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CLOFENOXYDE | CLOFENOXYDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GW7074 | CHEMBL72365 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CETRIMIDE | CETRIMIDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BENZIODARONE | BENZIODARONE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-4579 | CHEMBL584626 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | AMYLMETACRESOL | AMYLMETACRESOL | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BEXAROTENE | BEXAROTENE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DITHIAZANINE | DITHIAZANINE | |